IVDCDMO Team

In today’s highly competitive healthcare and biotechnology landscape, speed-to-market has become one of the most decisive factors influencing commercial success. This is particularly true in the in vitro diagnostics (IVD) industry, where technological innovation, regulatory pressure, evolving disease patterns, and global market demand continue to accelerate product development cycles. For many IVD companies, especially startups and innovation-driven biotechnology firms, bringing a diagnostic p...

In modern in vitro diagnostics (IVD), immunoassay technologies play a central role in disease screening, clinical diagnosis, biomarker monitoring, and public health surveillance. Among the most widely adopted platforms, Chemiluminescent Immunoassay (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), and Fluorescence Immunoassay (FIA) represent three foundational technologies used across hospitals, diagnostic laboratories, research institutions, and point-of-care testing (POCT) environments. Altho...

In the global medical device and in vitro diagnostics (IVD) industry, regulatory compliance is no longer simply a legal obligation — it has become a fundamental requirement for market access, product credibility, and long-term business sustainability. Among all internationally recognized quality standards, International Organization for Standardization 13485 stands as one of the most important frameworks governing quality management systems for medical device manufacturers and related service...